Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Janux Therapeutics, Inc. (JANX : NSDQ)

• Company Description    Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif. Number of Employees: 60

• Price / Volume Information    Yesterday's Closing Price: $12.10 Daily Weekly Monthly 20 Day Moving Average: 213,152 shares Shares Outstanding: 41.83 (millions) Market Capitalization: $506.18 (millions) Beta: 1.53 52 Week High: $23.64 52 Week Low: $9.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.97% -21.07% 12 Week -14.28% -20.42% Year To Date -8.12% -16.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10955 Vista Sorrento Parkway Suite 200 - San Diego,CA 92130 USA ph: 858-751-4493 fax: - investors@januxrx.com http://www.januxrx.com

• General Corporate Information    Officers David Campbell - President and Chief Executive Officer and Director Jay Lichter - Chairman Tighe Reardon - Acting Chief Financial Officer Vickie Capps - Director Winston Kung - Director Peer Information Janux Therapeutics, Inc. (CORR.) Janux Therapeutics, Inc. (RSPI) Janux Therapeutics, Inc. (CGXP) Janux Therapeutics, Inc. (BGEN) Janux Therapeutics, Inc. (GTBP) Janux Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 47103J105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/08/23 Share - Related Items Shares Outstanding: 41.83 Most Recent Split Date: (:1) Beta: 1.53 Market Capitalization: $506.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.35 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.63 Price/Cash Flow: - Price / Sales: 55.80 EPS Growth vs. Year Ago Period: -31.25% vs. Previous Quarter: -7.69% Sales Growth vs. Year Ago Period: 28.89% vs. Previous Quarter: -28.01% ROE 03/31/23 - -20.31 12/31/22 - -18.43 09/30/22 - -17.29 ROA 03/31/23 - -17.96 12/31/22 - -16.69 09/30/22 - -16.01 Current Ratio 03/31/23 - 19.94 12/31/22 - 20.14 09/30/22 - 21.08 Quick Ratio 03/31/23 - 19.95 12/31/22 - 20.14 09/30/22 - 21.08 Operating Margin 03/31/23 - -731.63 12/31/22 - -723.61 09/30/22 - -818.23 Net Margin 03/31/23 - -731.63 12/31/22 - -723.61 09/30/22 - -818.23 Pre-Tax Margin 03/31/23 - -739.81 12/31/22 - -732.22 09/30/22 - -818.23 Book Value 03/31/23 - 7.44 12/31/22 - 7.70 09/30/22 - 7.96 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©